NCT04585737View on ClinicalTrials.gov

Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF

PHASE4CompletedINTERVENTIONAL

Enrollment

222

Participants

Timeline

Start Date

October 5, 2020

Primary Completion Date

August 3, 2023

Study Completion Date

August 10, 2023

Conditions

HIV I Infection

Interventions

DRUG

Dolutegravir / Lamivudine Pill

Experimental

DRUG

Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill

Active comparator

Trial Locations (1)

32803

Orlando Immunology Center, Orlando

Sponsors

Collaborators (1)

ViiV Healthcare

All Listed Sponsors

collaborator

ViiV Healthcare

INDUSTRY

lead

Charlotte-Paige Rolle, MD

OTHER